Myobloc, known as Neurobloc in Europe, is a member of the botulinum toxin family. It has been used for a myriad of problems since its approval in the United States in December 2000. It is currently not approved for cosmetic use but has been used for this purpose. This article reviews what is currently known about botulinum toxin type B and its efficacy and safety.
BOTULINUM TOXIN type B (BTX-B) is one of seven antigenically distinct serotypes of toxin produced by the bacteria Clostridium botulinum. All seven types of botulinum toxin exert their effects at the neuromuscular junction, where they interact with type-specific proteins in the SNARE (soluble N-ethlymaleimide sensitive factor attachment protein receptor), comprised of synaptobrevin, SNAP-25, and syntaxin. An intact SNARE complex is necessary for the release of acetylcholine into the neuromuscular junction. BTX-B cleaves a protein component of the SNARE complex known as synaptobrevin. This interruption blocks the release of acetylcholine, a substance that is necessary for muscle contraction and sweating. The effects of BTX-B are temporary, usually lasting from 2 to 5 months. 1, 2 BTX-B is sold in the United States under the trade name of Myobloc (Elan Pharmaceuticals, San Diego, CA). Myobloc was approved in 2000 for the treatment of cervical dystonia in the United States by the Food and Drug Administration, 3 but it is often used as an off-label treatment for facial wrinkles and hyperhidrosis (excessive sweating). Myobloc is packaged as a ready-to-use solution in three different vial presentations. Each vial is overfilled and actually contains more BTX-B than is stated on the label. The smallest vial is labeled to contain 2,500 U in 0.5 mL; however, it actually contains 0.82 mL (4,100 U). The 5,000-U (1.0 mL) vial contains 6,800 U in 1.36 mL, and the 10,000-U (2.0 mL) vial actually contains 12,650 U in 2.53 mL. It is important to note that the vials are overfilled because dilution of Myobloc in the vial could result in a higher concentration of BTX-B than expected if the overfill is not taken into account. Although Myobloc can be used undiluted, dilution with preservative containing saline reduces the pain on injection and is therefore recommended by the author. Studies have shown that unopened Myobloc vials are stable for 30 months when refrigerated and 9 months at room temperature. 4 
BTX-B in Animal Studies
Many animal studies have been performed to evaluate the efficacy of BTX-B. A comparative study in mice evaluated the duration of action of BTX-A and BTX-B in mice. The mice were injected with BTX-A or BTX-B. A digit abduction scoring assay was used to measure muscle contraction in the hands of the mice. It was found that both BTX-A and BTX-B were effective in lessening the muscle contractions of the mice. The duration of action of BTX-A was 36 days, and the duration with BTX-B was 14 days. 5 Some physicians have given anecdotal reports that Myobloc diffuses more than that seen with Botox. In order to evaluate the diffusion of BTX-B, a monkey study was conducted. Monkeys were injected into the abductor pollicis brevis muscle with BTX-A or BTX-B to determine the MED (defined as the quantity needed to induce 75% reduction in the amplitude of the evoked compound muscle action potential). 6 The MED was determined to be 0.09 U of Botox and 0.44 U of Myobloc. The monkeys were then injected with each toxin in opposite hands, at doses ranging from the MED to 25 times the MED. The amplitude of the action potential (CMAP) was determined for the injected muscle (abductor pollicis brevis), an adjacent muscle (FDI), and a muscle on the opposite side of the palm (ADM). The mean CMAP in FDI was reduced by 92.7% (BTX-B) and 57.3% (BTX-A). The action potential measured in the muscle on the opposite side of the palm (ADM) was used as an indicator of diffusion because the toxin would have had to diffuse from one side of the hand to the other to affect this muscle. The mean action potential (CMAP) in the ADM muscle was reduced by 58.3% by BTX-A but only by 2% by BTX-B. This suggested less diffusion of BTX-B than BTX-A. Although these animal studies give us information about the properties of BTX-B, we do not know how these studies translate to the human experience. In addition, the size of the muscles used in the studies may affect the results. At this time, similar studies in humans have not been performed, and thus, the animal data must be interpreted with caution.
BTX-B for Cervical Dystonia
Interest in the use of BTX-B as a treatment for cervical dystonia increased when it became evident that some patients were producing antibodies against BTX-A, therefore becoming resistant to treatment. Several small preliminary dose-escalation studies were conducted to evaluate the safety and efficacy of increasing doses of BTX-B in the late 1990s. These studies, which involved a total of 48 participants receiving varying doses of BTX-B, found that it was safe and effective in the treatment of cervical dystonia. Side effects reported by participants included dysphagia, tremor, hematoma, neck pain, asthenia, nausea, hypertonia, and injection site pain. [7] [8] [9] Before approval of BTX-B, three randomized, double-blind, placebo-controlled clinical trials were conducted to evaluate the safety and efficacy of BTX-B for the treatment of cervical dystonia. The first trial involved 122 BTX-A-responsive and BTX-A-resistant participants treated with either placebo or 2,500, 5,000, or 10,000 U of BTX-B. The study found that participants in all three treatment groups had improved at 4 weeks and that the level of improvement increased with increasing dosage. Reported adverse events included dry mouth and dysphagia, and adverse events increased with increasing dose. 10 The second trial involved 109 type A-responsive participants treated with either placebo, 5,000 U, or 10,000 U of BTX-B. This study also found significant improvement in cervical dystonia at 4 weeks, with treatment duration lasting from 12 to 16 weeks. The adverse events reported in this study included dysphagia and dry mouth, and these increased as the dose increased. 11 The third study involved 77 participants who were no longer responsive to BTX-A; this study compared the safety and efficacy of 10,000 U of BTX-B versus placebo. The study found significant improvements in cervical dystonia in the treatment group at Week 4 and a treatment duration of 12 to 16 weeks. The adverse events reported in this study included dry mouth and dysphagia. 12 The incidence of reported dry mouth in these three cervical dystonia studies was 16%. These events were mild to moderate in intensity and were self-resolving. 13 This observation is supported by the results of studies involving mice; those mice injected with a BTX-B preparation were observed to gather around the water bottle after injection. 14 Critics of this study state that the BTX-B used was not Myobloc, and the observation could have been caused by the fact that the substance used contained more protein than is found in the commercially available Myobloc.
BTX-B for Facial Wrinkles
BTX-B has been used as an off-label indication for the temporary correction of facial wrinkles. Preliminary results from studies involving 60 participants in New York have found that Myobloc is effective for the reduction of crow's feet wrinkles, forehead lines, lines on the lower eyelid and upper lip, and bands around the chin and neck. Investigators reported in a nonpeer-reviewed publication that the wrinkles improved between 48 and 72 hours after treatment and that the duration of this improvement was from 3 to 4 months. 15 Preliminary results from another study conducted in San Francisco involving 24 participants treated with BTX-B for facial lines in three areas found that diluted Myobloc was safe and effective for the treatment of facial lines. Glabellar lines were significantly improved at Weeks 1 and 2, but the changes as rated by investigators were no longer significant by Week 8 and had returned to baseline by Week 12. Crow's feet wrinkles also improved by 1.69 points at 1 week after treatment but returned to baseline levels by Week 12. Forehead wrinkles treated with BTX-B showed statistically significant improvements versus baseline between Weeks 1 and 8 but had also returned to baseline levels by the Week 12 observation. The investigators concluded that Myobloc was safe and effective for the treatment of glabellar, crow's feet, and forehead facial wrinkles but felt that the short duration of effect might have been due to the dilution of the Myobloc. There were no reports of dysphagia, dyspepsia, or dry mouth among study participants. 16 A recent study by Sadick 17 evaluated a single set dose of BTX-B in the treatment of glabellar (frown) lines. Thirty patients were injected in six sites with 300 U per site for a total dose of 1,800 U. At 2 and 4 weeks, patient and physician assessment scores showed an average score of 2 (''complete disappearance of wrinkles''). Three patients reported mild adverse events. The mean duration of effect with this low dose of BTX-B was 8 weeks.
A study by Lowe et al. 18 compared patients injected in the glabella with BTX-B in two different dose conversions against BTX-A. Some patients received a total of 1,000 U to the glabella, whereas others received a total of 2,000 U. The patients treated with BTX-A (Botox) received a total dose of 20 U to the glabellar region. These patients were clinically assessed at pretreatment, Day 3, 1 week, 4 weeks, 12 weeks, and 16 weeks after treatment. Both types of botulinum toxin were effective at improving glabellar frown lines; however, the onset of action occurred slightly sooner (2 to 3 days) with Myobloc (BTX-B) than with Botox, BTX-A (3 to 7 days). The duration of effect seen with 20 U of BTX-A was 16 weeks or more. With 1,000 U of BTX-B, the dose duration was 6 to 8 weeks, and with 2,000 U of BTX-B, the duration was 10 to 12 weeks. The authors concluded that BTX-B had a quicker onset of action, but BTX-A had longer duration of action at the doses studied. The authors stated that controlled dose ranging should be conducted in a larger patient population before the duration of action of BTX-B can be compared with the duration BTX-A.
A pilot study conducted at the University of Miami in Florida assessed the safety and efficacy of undiluted Myobloc for the treatment of crow's feet wrinkles. In this study, 20 volunteers were treated with either 1,500 U of Myobloc or placebo in three injection sites in the crow's feet area (500 U at each injection site). The placebo group was included in order to compare the incidence of side effects between the two groups. Participants who did not respond to the initial injection (placebo) were reinjected with 1,500 U of Myobloc on Day 30. Myobloc-treated participants experienced an average wrinkle correction of 2.1 points (scale of 1 to 4), with maximum effect seen at Day 30 and a return to baseline wrinkle scores at between the Day 90 and Day 120 follow-up visits. Treatment with Myobloc was generally well tolerated. All of the study participants were specifically asked about a list of side effects. Adverse events attributable to Myobloc were dry mouth (reported by 45% of participants), dry eyes (reported by 25% of participants), and bruising (reported by 25% of participants). 19 With the exception of bruising, these adverse events have not been commonly associated with the use of BTX-A. It is currently unknown why these side effects occur with BTX-B. A comparison to BTX-A was not done because the comparable dose of BTX-B to BTX-A is currently not known. This pilot study demonstrates that the proper dose of Myobloc for the treatment of crow's feet wrinkles is currently not known.
All of these studies seem to agree that more data are needed before the conversion ratio of Myobloc units to Botox units is known for facial wrinkles. Once the comparable dose is determined, duration data can then be ascertained, and meaningful clinical trials can be conducted.
BTX-B for Hyperhidrosis
The botulinum toxins affect sweat production by blocking the release of acetylcholine in the postganglionic sympathetic fibers in the sweat glands. There have been no studies published to date on the effects of BTX-B on hyperhidrosis. 20 However, preliminary results from a pilot study conducted with 20 volunteers at the University of Miami have shown that Myobloc is effective in the treatment of hyperhidrosis. The duration of this effect is currently unknown, as the study is ongoing. Studies evaluating the efficacy and safety of Myobloc for palmar hyperhidrosis are also ongoing.
Summary BTX-B has been shown to improve neck spasms in cervical dystonia and to treat facial wrinkles (Figures 1-4) . Much more is known about the use of Myobloc for cervical dystonia than is known about the 
